Item 7.01. Regulation FD Disclosure.

On September 27, 2022, the Company issued a press release entitled "Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout". A copy of the Company's press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.


--------------------------------------------------------------------------------

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits

Exhibit
  No.     Description

99.1        Press Release issued by the Company
          on September 27, 2022, furnished
          herewith.

104       Cover Page Interactive Data File
          (embedded within the Inline XBRL
          document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses